Swedish trial on embolization of middle meningeal artery versus surgical evacuation in chronic subdural hematoma (SWEMMA)-a national 12-month multi-center randomized controlled superiority trial with parallel group assignment, open treatment allocation and blinded clinical outcome assessment

Mattias Drake, Teresa Ullberg, Henrietta Nittby, Niklas Marklund, Johan Wassélius, Mattias Drake, Teresa Ullberg, Henrietta Nittby, Niklas Marklund, Johan Wassélius

Abstract

Background: Chronic subdural hematoma (cSDH) is one of the most common neurosurgical disorders and the incidence is rising. The routine treatment is neurosurgical hematoma evacuation, which is associated with recurrence rates up to 10-25%. In recent years, endovascular embolization of the middle meningeal artery (eMMA) has garnered much attention due to recurrence rates as low as < 5%. Several randomized controlled trials are planned or ongoing. In most of these trials, conventional neurosurgical treatment with or without adjunctive endovascular embolization is compared. The proposed trial aims to conduct a head-to-head comparison between neurosurgical and endovascular treatment as stand-alone treatments.

Methods: The trial is academically driven and funded within existing public healthcare systems and infrastructure. Patients with uni- or bilateral cSDH, presenting with mild-to moderate symptoms, and admitted to neurosurgery on clinical grounds will be offered participation. Subjects are randomized 1:1 between conventional neurosurgical treatment (control) and endovascular embolization of the middle meningeal artery (intervention). Primary endpoint is reoperation due to clinically and/or radiologically significant recurrence within 3 months. Secondary endpoints include safety, technical success rate, neurological disability, and quality of life.

Discussion: There are mounting retrospective data suggesting eMMA, as sole treatment or as an adjunctive to neurosurgery for cSDH, is safe and effective with a reoperation rate lower than neurosurgical hematoma evacuation alone. If randomized controlled trials confirm these findings, there is a potential for a paradigm shift in the treatment of cSDH where a minimally invasive procedure can replace open surgery in a large and oftentimes old and fragile patient cohort.

Trial registration: ClinicalTrials.gov, ClinicalTrials.gov Identifier NCT05267184 . Registered March 4, 2022.

Keywords: Burr hole; Chronic subdural hematoma; Embolization; Endovascular; Middle meningeal artery; Neurosurgery.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

References

    1. Rauhala M, Luoto TM, Huhtala H, Iverson GL, Niskakangas T, Ohman J, et al. The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population. J Neurosurg. 2019;132(4):1147–1157. doi: 10.3171/2018.12.JNS183035.
    1. Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J Neurosurg. 2015;123(5):1209–1215. doi: 10.3171/2014.9.JNS141550.
    1. Almenawer SA, Farrokhyar F, Hong C, Alhazzani W, Manoranjan B, Yarascavitch B, et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg. 2014;259(3):449–457. doi: 10.1097/SLA.0000000000000255.
    1. Feghali J, Yang W, Huang J. Updates in chronic subdural hematoma: epidemiology, etiology, pathogenesis, treatment, and outcome. World Neurosurg. 2020;141:339–345. doi: 10.1016/j.wneu.2020.06.140.
    1. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017;14(1):108. doi: 10.1186/s12974-017-0881-y.
    1. Moshayedi P, Liebeskind DS. Middle meningeal artery embolization in chronic subdural hematoma: implications of pathophysiology in trial design. Front Neurol. 2020;11:923. doi: 10.3389/fneur.2020.00923.
    1. Shotar E, Meyblum L, Premat K, Lenck S, Degos V, Grand T, et al. Middle meningeal artery embolization reduces the post-operative recurrence rate of at-risk chronic subdural hematoma. J Neurointerv Surg. 2020;12(12):1209–1213.
    1. Link TW, Boddu S, Paine SM, Kamel H, Knopman J. Middle meningeal artery embolization for chronic subdural hematoma: a series of 60 cases. Neurosurgery. 2019;85(6):801–807. doi: 10.1093/neuros/nyy521.
    1. Kim E. Embolization therapy for refractory hemorrhage in patients with chronic subdural hematomas. World Neurosurg. 2017;101:520–527. doi: 10.1016/j.wneu.2017.02.070.
    1. Ban SP, Hwang G, Byoun HS, Kim T, Lee SU, Bang JS, et al. Middle meningeal artery embolization for chronic subdural hematoma. Radiology. 2018;286(3):992–999. doi: 10.1148/radiol.2017170053.
    1. Haldrup M, Ketharanathan B, Debrabant B, Schwartz OS, Mikkelsen R, Fugleholm K, et al. Embolization of the middle meningeal artery in patients with chronic subdural hematoma-a systematic review and meta-analysis. Acta Neurochir (Wien) 2020;162(4):777–784. doi: 10.1007/s00701-020-04266-0.
    1. Joyce E, Bounajem MT, Scoville J, Thomas AJ, Ogilvy CS, Riina HA, et al. Middle meningeal artery embolization treatment of nonacute subdural hematomas in the elderly: a multiinstitutional experience of 151 cases. Neurosurg Focus. 2020;49(4):E5. doi: 10.3171/2020.7.FOCUS20518.
    1. Dian J, Linton J, Shankar JJ. Risk of recurrence of subdural hematoma after EMMA vs surgical drainage - systematic review and meta-analysis. Interv Neuroradiol. 2021;27(4):577–583. doi: 10.1177/1591019921990962.
    1. Kan P, Maragkos GA, Srivatsan A, Srinivasan V, Johnson J, Burkhardt JK, et al. Middle meningeal artery embolization for chronic subdural hematoma: a multi-center experience of 154 consecutive embolizations. Neurosurgery. 2021;88(2):268–277. doi: 10.1093/neuros/nyaa379.
    1. . U.S. National Library of Medicine. . Accessed 5 Apr 2022.
    1. Markwalder TM. The course of chronic subdural hematomas after burr-hole craniostomy with and without closed-system drainage. Neurosurg Clin N Am. 2000;11(3):541–546. doi: 10.1016/S1042-3680(18)30120-7.
    1. Zolfaghari S, Stahl N, Nittby RH. Does time from diagnostic CT until surgical evacuation affect outcome in patients with chronic subdural hematoma? Acta Neurochir (Wien) 2018;160(9):1703–1709. doi: 10.1007/s00701-018-3620-y.
    1. Saver JL, Filip B, Hamilton S, Yanes A, Craig S, Cho M, et al. Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA) Stroke. 2010;41(5):992–995. doi: 10.1161/STROKEAHA.109.571364.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343. doi: 10.3109/07853890109002087.
    1. Catapano JS, Koester SW, Srinivasan VM, Rumalla K, Baranoski JF, Rutledge C, et al. Total 1-year hospital cost of middle meningeal artery embolization compared to surgery for chronic subdural hematomas: a propensity-adjusted analysis. J Neurointerv Surg. 2022;14(8):804–6.
    1. Zolfaghari S, Bartek J, Jr, Djarf F, Wong SS, Strom I, Stahl N, et al. Risk factors for need of reoperation in bilateral chronic subdural haematomas. Acta Neurochir (Wien) 2021;163(7):1849–1856. doi: 10.1007/s00701-021-04811-5.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다